Medicine Cabinet Sovereignty: Securing Europe’s Drug Supply Against the Next Crisis

The Covid-19 pandemic exposed a dependency few Europeans had thought about before it mattered: a large share of the active pharmaceutical ingredients in common medicines — antibiotics, painkillers, blood pressure drugs — are manufactured in India and China, even when the finished pills are packaged and branded as European. Early in the pandemic, export restrictions from producing countries and a scramble for masks, ventilators, and eventually vaccines showed how quickly medical supply chains can seize up under pressure, and how little buffer Europe had built into a system optimized for efficiency over resilience. Securing supply in future crises means treating pharmaceutical and health security the way Europe now treats energy security — as a strategic vulnerability, not just a market outcome.

Bringing Essential Medicine Production Back to Europe

Generic drugs — the off-patent medicines that make up the bulk of prescriptions by volume — are also the ones most likely to have their active ingredients sourced from a small number of Asian manufacturers, precisely because intense price competition on generics has pushed production toward the lowest-cost locations over decades. This is a structurally difficult problem: European-made generics would likely cost more, and health systems and insurers have strong incentives to keep purchasing costs down, which is exactly what drove production abroad in the first place.

The EU’s Critical Medicines Act, adopted in 2025, attempts to address this by identifying a list of medicines considered critical for health security and offering incentives, including preferential treatment in public procurement, for manufacturers who produce them within Europe. Whether this shifts meaningful production back will depend on whether the incentives are large enough to offset the persistent cost gap — a gap that, unlike in semiconductors, is measured in cents per pill rather than the enormous margins that make chip subsidies more straightforward to justify politically.

Emergency Stockpiles

Even with expanded domestic production, some level of import dependency is likely to remain, which makes strategic stockpiles of critical medicines, personal protective equipment, and medical supplies a necessary complement rather than a substitute. The early pandemic scramble for masks and ventilators demonstrated what happens without them: national governments competing against each other for the same scarce global supply, sometimes literally outbidding allies at airport tarmacs for shipments.

The EU’s rescEU mechanism, expanded significantly after the pandemic, now maintains common European stockpiles of medical countermeasures intended to be distributed according to need rather than left to a scramble between member states. The ongoing challenge is less about establishing the concept and more about funding it adequately during calm periods, when stockpiling inevitably competes for budget against more visible, immediate health spending priorities.

Domestic Vaccine Production

Europe was fortunate to have world-leading vaccine developers, including BioNTech and Sanofi, during Covid-19, but even so, early rollout was slowed by manufacturing bottlenecks, export controls from other producing nations, and contractual disputes over doses that had been promised to Europe but diverted elsewhere. The lesson was not that European vaccine science failed — it largely succeeded — but that manufacturing scale-up and raw material supply chains for things like lipid nanoparticles and bioreactor components were not resilient enough to match the science.

Building on this means maintaining “warm base” manufacturing capacity — production lines that can be rapidly repurposed for a new vaccine during an emergency rather than built from scratch each time — along with securing the upstream supply chains for vaccine manufacturing inputs, some of which face the same concentrated sourcing problems as pharmaceutical ingredients more broadly.

Joint Procurement Arrangements

The EU’s joint vaccine procurement during Covid-19 — negotiating contracts collectively on behalf of member states rather than each country bargaining separately — is often cited as one of the pandemic response’s clearer successes, giving smaller member states access to the same negotiating leverage and pricing as larger ones, and avoiding the scenario where wealthier countries simply outbid poorer neighbors for scarce doses.

Extending this model beyond emergency vaccine procurement to routine critical medicine purchasing could give Europe similar leverage in negotiating with pharmaceutical manufacturers and in signaling reliable, large-scale demand to any manufacturer considering building capacity in Europe under the Critical Medicines Act. The trade-off is a familiar one across this whole series: joint procurement requires member states to cede some independent negotiating flexibility in exchange for collective bargaining power, a trade some national health ministries have been more willing to accept than others.

Conclusion

Pharmaceutical security differs from many of the other sectors in this series in one important way: the cost of getting it wrong is measured directly in lives during the next crisis, not just economic disruption. Bringing essential production home, maintaining real stockpiles, keeping vaccine manufacturing capacity warm, and negotiating jointly all address different failure points exposed by the pandemic — sourcing, buffer capacity, scale-up speed, and bargaining power respectively. None of them guarantees Europe sails through the next health emergency smoothly, but together they replace the scramble of 2020 with something closer to a plan.